Side-by-side comparison of AI visibility scores, market position, and capabilities
Daytona Beach FL insurance brokerage (NYSE: BRO) $4.5B FY2024 revenue (+12%); decentralized acquisition model, National Programs specialty, 30-year consistent growth competing with Marsh McLennan and Aon.
Brown & Brown, Inc. is a Daytona Beach, Florida-based insurance brokerage and risk management company — publicly traded on the New York Stock Exchange (NYSE: BRO) as an S&P 500 Financials component — providing insurance brokerage, risk management consulting, and third-party claims administration services to businesses and individuals across the United States, Canada, the UK, Ireland, and Bermuda through approximately 16,000 employees at 500+ offices. In fiscal year 2024, Brown & Brown reported revenues of $4.5 billion (+12% organic growth) — continuing its 30-year track record of consistent organic and acquisition-driven revenue growth that has made Brown & Brown one of the fastest-growing large insurance brokers in the US, growing from $1B revenue in 2015 to $4.5B in 2024 through organic growth compounding and disciplined acquisition integration. CEO Powell Brown (son of founder Hyatt Brown, representing the family's generational leadership of the company) leads Brown & Brown's distinctive "decentralized" operating model where each acquired insurance agency retains its local brand identity, leadership team, and community relationships while benefiting from Brown & Brown's national carrier relationships, compliance infrastructure, shared technology, and capital for further acquisition. Brown & Brown's four business segments — Retail (local commercial insurance for small-to-midsize businesses), National Programs (specialty program insurance distributed through managing general agents for specific industries — veterinarians, dentists, pest control, construction), Wholesale Brokerage (surplus lines excess and specialty placement for non-admitted risks), and Services (third-party claims administration) — provide diversified revenue across insurance distribution channels that smooth individual market cycle volatility.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.